4.4 Review

Common gene pathways and families altered by DNA methylation in breast and prostate cancers

Journal

ENDOCRINE-RELATED CANCER
Volume 20, Issue 5, Pages R215-R232

Publisher

BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-13-0204

Keywords

breast; prostate; biomarker; gene regulation; neoplasia

Funding

  1. Prostate Cancer Foundation of Australia Young Investigator Grant [YIG03]
  2. United States Department of Defense Prostate Cancer Research Program Training Fellowship [PC080400]
  3. University of Adelaide Barbara Kidman Fellowship
  4. W Bruce Hall Cancer Council of South Australia Research Fellowship
  5. Cancer Council SA
  6. SAHMRI Beat Cancer Project [APP1030945]

Ask authors/readers for more resources

Epigenetic modifications, such as DNA methylation, are widely studied in cancer as they are stable and easy to measure genome wide. DNA methylation changes have been used to differentiate benign from malignant tissue and to predict tumor recurrence or patient outcome. Multiple genome wide DNA methylation studies in breast and prostate cancers have identified genes that are differentially methylated in malignant tissue compared with non-malignant tissue or in association with hormone receptor status or tumor recurrence. Although this has identified potential biomarkers for diagnosis and prognosis, what is highlighted by reviewing these studies is the similarities between breast and prostate cancers. In particular, the gene families/pathways targeted by DNA methylation in breast and prostate cancers have significant overlap and include homeobox genes, zinc finger transcription factors, S100 calcium binding proteins, and potassium voltage-gated family members. Many of the gene pathways targeted by aberrant methylation in breast and prostate cancers are not targeted in other cancers, suggesting that some of these targets may be specific to hormonal cancers. Genome wide DNA methylation profiles in breast and prostate cancers will not only define more specific and sensitive biomarkers for cancer diagnosis and prognosis but also identify novel therapeutic targets, which may be direct targets of agents that reverse DNA methylation or which may target novel gene families that are themselves DNA methylation targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available